InvestSMART

LTR Pharma Ltd (ASX: LTP) - Announcements

Current share price for LTP : $0.475 0.015 (3.06%)+

ASX company news and announcements for LTR Pharma Ltd (LTP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All LTR Pharma Ltd (LTP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than LTR Pharma Ltd (LTP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for LTR Pharma Ltd (LTP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$86 Proposed issue of securities - LTP 10 Dec 2024 9:07AM $1.050 $0.475 fallen by 54.76%
$86 LTR Pharma Announces Successful A$25 million Placement 10 Dec 2024 9:07AM $1.050 $0.475 fallen by 54.76%
$86 Change of Director's Interest Notices 9 Dec 2024 5:23PM $1.050 $0.475 fallen by 54.76%
$86 Notification regarding unquoted securities - LTP 9 Dec 2024 5:22PM $1.050 $0.475 fallen by 54.76%
$86 Trading Halt 6 Dec 2024 8:42AM $1.050 $0.475 fallen by 54.76%
$86 Ord Minnett Biotechnology Conference Presentation 28 Nov 2024 9:37AM $1.250 $0.475 fallen by 62%
$86 Results of Meeting 27 Nov 2024 4:27PM $1.250 $0.475 fallen by 62%
$86 AGM Presentation 27 Nov 2024 2:17PM $1.195 $0.475 fallen by 60.25%
$86 JV with Leading Men's Health Group for Online Platform 12 Nov 2024 8:27AM $1.535 $0.475 fallen by 69.06%
$86 Annual Report to shareholders 28 Oct 2024 5:07PM $1.170 $0.475 fallen by 59.40%
$86 Notice of Annual General Meeting/Proxy Form 28 Oct 2024 5:03PM $1.170 $0.475 fallen by 59.40%
$86 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2024 8:40AM $1.305 $0.475 fallen by 63.60%
$86 SPONTAN Final Study Results 14 Oct 2024 9:04AM $1.930 $0.475 fallen by 75.39%
$86 Appendix 4G and Corporate Governance Statement 30 Aug 2024 9:29AM $1.770 $0.475 fallen by 73.16%
$86 FY24 Results Announcement 30 Aug 2024 9:29AM $1.770 $0.475 fallen by 73.16%
$86 Appendix 4E and Annual Financial Report 30 Aug 2024 9:27AM $1.770 $0.475 fallen by 73.16%
$86 SPONTAN Prescribed to First Patient by Authorised Prescriber 16 Aug 2024 9:05AM $1.375 $0.475 fallen by 65.45%
$86 LTP Secures Global CoDevelopment Agreement with Aptar Pharma 13 Aug 2024 9:17AM $0.965 $0.475 fallen by 50.78%
$86 Mens Health Expert Prescribes SPONTAN 8 Aug 2024 9:16AM $0.790 $0.475 fallen by 39.87%
$86 SPONTAN prescribed to First Patient Under TGA 5 Aug 2024 9:02AM $0.730 $0.475 fallen by 34.93%
$86 Cleansing Notice 31 Jul 2024 11:42AM $0.770 $0.475 fallen by 38.31%
$86 Application for quotation of securities - LTP 31 Jul 2024 11:36AM $0.770 $0.475 fallen by 38.31%
$86 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2024 9:35AM $0.880 $0.475 fallen by 46.02%
$86 Investor Webinar 24 Jul 2024 10:33AM $0.800 $0.475 fallen by 40.63%
$86 Investor Presentation 24 Jul 2024 9:09AM $0.900 $0.475 fallen by 47.22%

76 - 100 of 138 results

Page 4 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.